Detail akcie Fate Therapeutics online

Business Summary: Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Fate Therapeutics Inc revenues decreased 34% to $63.5M. Net loss decreased 43% to $160.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research & Development decrease of 44% to $151.7M (expense), Stock-based Compensation in R&D decrease of 59% to $20.8M (expense).